Securities Class Action Filed Against Replimune Group, Inc.
Faruqi & Faruqi, LLP is investigating potential claims against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL) and reminds investors of the September 22, 2025 deadline to seek the role of lead plaintiff in a federal securities class action. The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that the IGNYTE trial was inadequately controlled, resulting in the FDA deeming it inadequate.
Key Takeaways:
- The lawsuit claims that investors suffered damages when the true details of the IGNYTE trial's prospects entered the market.
- On July 22, 2025, Replimune issued a press release stating that the FDA had issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RP1, indicating that the IGNYTE trial was not an adequate and well-controlled clinical investigation.
- The stock plummeted over 73% during intraday trading on July 22, 2025.
- Faruqi & Faruqi, LLP is a leading national securities law firm that has recovered hundreds of millions of dollars for investors since its founding in 1995.
- Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
Statistics:
- 73%: the stock price drop during intraday trading on July 22, 2025.
- September 22, 2025: the deadline to seek the role of lead plaintiff in the federal securities class action.
- 1995: the year Faruqi & Faruqi, LLP was founded.
- Hundreds of millions of dollars: the aggregate amount recovered by Faruqi & Faruqi, LLP for investors since its founding.
Sources:
- Newsfile Corp. - September 8, 2025
- Faruqi & Faruqi, LLP (www.faruqilaw.com)